Thursday, August 21, 2014 Last update: 6:03 PM
FreshNews.com - All Company Technology News Since 1996

InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering

Companies mentioned in this article: InVivo Therapeutics Holdings Corp.

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- InVivo Therapeutics Holdings Corp. (NVIV) today announced that it intends to offer for sale equity securities in an underwritten public offering. In connection with this offering, InVivo intends to grant the underwriters an option to purchase an additional 15% of the securities sold in the offering. All securities in the offering are being offered by InVivo. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is acting as the sole book-running manager in the offering.

The securities to be sold in the offering described above are being offered by InVivo pursuant to an effective shelf registration statement that was previously filed with the SEC and was declared effective on January 19, 2012. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained, when available, from Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co‐invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the Company earned the David S. Apple Award from The American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.

Forward-Looking Statements

Statements made in this press release that do not describe historical facts or which apply prospectively are “forward-looking statements” within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and relate to future events or the Company’s future operating or financial performance. Any forward-looking statements contained herein are based on current expectation, and are subject to a number of risks and uncertainties. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ materially from current expectations include market receptivity to the proposed offering and the value of the Company’s common stock. Additional risk factors are included in InVivo’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and other filings InVivo makes with the SEC, including quarterly reports on Form 10-Q and current reports on Form 8-K. InVivo does not undertake to update these forward-looking statements.


Copyright © Business Wire 2014
Contact:

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com